Sanclemente G, Correa LA.
4. Smith CA, Smith TD, Smolak PJ, Friend D, Hagen H, Gerhart M, et al. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology. 1997;236:316-27. 5. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev. 1997;159:137-54. 6. Roberts JA. Histopathogenesis of mousepox. II. Cutaneous infection. Br J Exp Pathol. 1962;43:462-8. 7. Hahon N, Wilson BJ. Pathogenesis of variola in Macaca irus monkeys. Am J Hyg. 1960;71:69-80. 8. Roberts J.A. Histopathogenesis of mousepox. I. Respiratory infection. Br J Exp Pathol. 1962;43:451-61. 9. Westwood JC, Boulter EA, Bowen ET, Maber HB. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br J Exp Pathol. 1966;47:453-65. 10. Stanford MM, McFadden G, Karupiah G, Chaudhri G. Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol Cell Biol. 2007;85:93-102. 11. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250-6. 12. Rahman MM, Jeng D, Singh R, Coughlin J, Essani K, McFadden G. Interaction of human TNF and beta2-microglobulin with Tanapox virus-encoded TNF inhibitor, TPV-2L. Virology. 2009;386:462-68. 13. Meyer-Hoffert U, Schwarz T, Schroder JM, Glaser R. Increased expression of human beta-defensin 3 in mollusca contagiosum. Clin Exp Dermatol. 2010; 35: 190-2. 14. Fenner F. The global eradication of smallpox. Med J Aust. 1980;1:455. 15. Downie AW, Meiklejohn G, St VL, Rao AR, Sundara Babu BV, Kempe CH. Smallpox frequency and severity in relation to A, B and O blood groups. Bull World Health Organ. 1965;33:623-5. 16. Deria A, Jezek Z, Markvart K, Carrasco P, Weisfeld J. The world's last endemic case of smallpox: surveillance and containment measures. Bull World Health Organ. 1980;58:279-83. 17. Breman JG, Henderson DA. Poxvirus dilemmas--monkeypox, smallpox, and biologic terrorism. N Engl J Med. 1998;339:556-9. 18. Diven DG. Poxviruses. In: Tyring S, editor. Mucocutaneous manifestations of viral diseases. New York: Marcel Dekker; 2002. p. 39-68. 19. Grayson W, Calonje E, Mckee PH. Infectious diseases of the skin. In: Mckee PH, Calonje E, Granter SR, editors. Pathology of the skin: with clinical correlations. Third edition. London: Mosby Elsevier Health Science; 2005. p. 860-7. 20. Pinkus H, Mehregan A. Inflammatory virus diseases. In: Mehregan A, editor. A guide to dermatopathology. Third edition. New York: Appleton Century Crofts; 1981, p. 146-7. 21. Weedon D. Viral diseases. Weedon skin pathology. Third edition. Edinburgh: Churchill Livingstone; 2002. p. 608-13. 22. Xiaowei X, Erickson L, Lianjun C, Elder DE. Diseases caused
76
Rev Asoc Colomb Dermatol. 2010;18: 67-7.
by viruses. In: Elder DE, Elenitsas R, Johnson BL Jr., Murphy GF, Xu X, editors. Histopathology of the skin. Tenth edition. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 646-65. 23. Sarkar JK, Mitra AC, Mukherjee MK, De SK, Mazumdar DG. Virus excretion in smallpox. 1. Excretion in the throat, urine, and conjunctiva of patients. Bull World Health Organ. 1973;48:517-22. 24. Meyer H, Damon IK, Esposito JJ. Orthopoxvirus diagnostics. Methods Mol Biol. 2004;269:119-34. 25. Parker S, Handley L, Buller RM. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol. 2008;3:595-612. 26. Medaglia ML, Pessoa LC, Sales ER, Freitas TR, Damaso CR. Spread of cantagalo virus to northern Brazil. Emerg Infect Dis. 2009;15:1142-3. 27. Silva-Fernandes AT, Travassos CE, Ferreira JM, Abrahao JS, Rocha ES, Viana-Ferreira F, et al. Natural human infections with Vaccinia virus during bovine vaccinia outbreaks. J Clin Virol. 2009;44:308-13. 28. Diven DG. An overview of poxviruses. J Am Acad Dermatol. 2001;44:1-16. 29. Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, OlsenRasmussen M, et al. A tale of two clades: monkeypox viruses. J Gen Virol. 2005;86:2661-72. 30. Parker S, Nuara A, Buller RM, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2007;2:17-34. 31. Reynolds MG, Davidson WB, Curns AT, Conover CS, Huhn G, Davis JP, et al. Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerg Infect Dis. 2007;13:1332-9. 32. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest. 2001;81:1581-600. 33. Damon IK. Poxviruses. In: Knipe DM, Howley PM, editors. Fields Virology. .Philadelphia: Lippincott Williams & Wilkins; 2007. 2947–75. 34. Baxby D, Bennett M, Getty B. Human cowpox 1969-93: a review based on 54 cases. Br J Dermatol. 1994;131:598-607. 35. Vorou RM, Papavassiliou VG, Pierroutsakos IN. Cowpox virus infection: an emerging health threat. Curr Opin Infect Dis. 2008;21:153-6. 36. Ninove L, Domart Y, Vervel C, Voinot C, Salez N, Raoult D, et al. Cowpox virus transmission from pet rats to humans, France. Emerg Infect Dis. 2009;15:781-4. 37. Nitsche A, Pauli G. Sporadic human cases of cowpox in Germany. Euro Surveill. 2007;12:E070419. 38. Baxby D, Bennett M. Poxvirus zoonoses. J Med Microbiol. 1997;46:17-33. 39. Beldomenico PM, Telfer S, Lukomski L, Gebert S, Bennett M, Begon M. Host condition and individual risk of cowpox virus infection in natural animal populations: cause or effect? Epidemiol Infect. 2009;137:1295-301. 40. Orf virus infection in humans--New York, Illinois, California, and Tennessee, 2004-2005. MMWR Morb Mortal Wkly Rep. 2006;55:65-8.
www.revistasocolderma.com